Edition:
Deutschland

Innoviva Inc (INVA.OQ)

INVA.OQ on NASDAQ Stock Exchange Global Select Market

13.61USD
22:00 Uhr
Change (% chg)

$-0.19 (-1.38%)
Prev Close
$13.80
Open
$13.69
Day's High
$13.88
Day's Low
$13.56
Volume
236,168
Avg. Vol
333,683
52-wk High
$15.60
52-wk Low
$7.58

About

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium... (more)

Buy/Sell

Sell Hold Buy
4.00 Mean rating from 1 analysts

Overall

Beta: 1.06
Market Cap(Mil.): $1,398.22
Shares Outstanding(Mil.): 101.32
Dividend: --
Yield (%): --

BRIEF-Innoviva Reports First Quarter 2020 Financial Results

* QTRLY EARNINGS PER SHARE $0.59 Source text for Eikon: Further company coverage:

BRIEF-Innoviva Says Co's 2020 Annual Meeting Of Stockholders Will Be Held In Virtual Meeting Format Only

* INNOVIVA INC - CO'S 2020 ANNUAL MEETING OF STOCKHOLDERS WILL BE HELD IN VIRTUAL MEETING FORMAT ONLY Source text for Eikon: Further company coverage:

BRIEF-GSK Says Filing Accepted By EMA For Trelegy Ellipta Use In Adult Patients With Asthma

* GSK FILING ACCEPTED BY EUROPEAN MEDICINES AGENCY FOR TRELEGY ELLIPTA USE IN ADULT PATIENTS WITH ASTHMA

Märkte

  • U.S.
  • Europa
  • Asien
  • Branchen

Branchenüberblick

Energie -0.09%
Rohstoffe -1.34%
Industrie -1.24%
Konjunktur abhängige Waren & Dienstleistungen +0.19%
Konjunktur unabhängige Waren & Dienstleistungen -1.97%
Finanzindustrie -0.83%
Pharma -0.72%
Technologie -0.43%
Telekommunikation -0.60%